A carregar...
Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis
Bevacizumab (BEV) is a key anti-angiogenic agent used in the treatment for recurrent glioblastoma multiforme (GBM). The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. We retrospec...
Na minha lista:
| Publicado no: | Neurol Med Chir (Tokyo) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Japan Neurosurgical Society
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8048115/ https://ncbi.nlm.nih.gov/pubmed/33658457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2176/nmc.oa.2020-0308 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|